MIT researchers develop a wireless implant that detects low blood sugar and releases glucagon, offering a potential safety ...

Vertex Pharmaceuticals' new therapy, zimislecel, has potential to be a "functional cure," experts say. To continue reading ...

The new implant contains a reservoir of glucagon that sits beneath the skin and can be activated in an emergency, with no need for injections. For individuals with Type 1 diabetes, the risk of ...

Although insulin and glucagon are also able to act as counter-regulatory hormones following hypoglycemia, it is mostly the adrenaline-driven mechanisms that restore normal glucose levels during ...

developing hypoglycemia, or low blood sugar, is an ever-present threat. When glucose levels become extremely low, it creates ...

Amycretin — a novel experimental molecular targeting both the glucagon-like peptide 1 (GLP-1) and the amylin receptor — has shown promise for weight management in early-phase clinical trials ...